How This Works
BPC-157 is a stable pentadecapeptide that promotes angiogenesis, modulates nitric oxide pathways, and demonstrates broad cytoprotective effects across gastrointestinal, musculoskeletal, and neurological tissues in preclinical models. It has shown activity at very low doses (nanogram to microgram per kilogram) without demonstrable toxicity in animal studies.
TB-500 (Thymosin Beta-4) is an actin-sequestering peptide that promotes cell migration, wound healing, and anti-inflammatory responses. It is well-tolerated in animal and early clinical studies, even at multi-milligram doses.
Combining these peptides may provide complementary mechanisms for tissue repair: BPC-157 for its trophic and anti-inflammatory effects, and TB-500 for enhanced cell migration and angiogenesis.
Potential Benefits & Side Effects
Observations from preclinical and limited clinical literature.
May support accelerated healing of tendons, ligaments, muscles, and soft tissue injuries.
Preclinical evidence suggests gastroprotective and anti-inflammatory properties for BPC-157.
TB-500 promotes wound healing and may reduce scarring through enhanced cell migration.
Both peptides are generally well tolerated; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
No significant toxicity has been documented up to high doses in animal studies.
Dosage Guide: https://help.purepeptide.st/en/articles/13206395-bpc-157-tb-500-10mg-blend-vial-dosage-protocol
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.